[6-K] CytoMed Therapeutics Limited Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Aware, Inc. (AWRE) – Form 4 insider transaction

Director Brian D. Connolly reported a single transaction dated July 1 2025 coded “M,” indicating the exercise of previously granted equity awards. Connolly acquired 25,671 common shares at a stated price of $0.00 per share, suggesting a cost-free option or restricted-stock conversion. Following the exercise, his directly held stake increased to 218,784 shares.

No shares were sold and no derivative positions remain disclosed in Table II, implying the move strictly augments Connolly’s long equity exposure. Insiders converting options without an immediate sale can be viewed as a moderate vote of confidence, although such exercises may also be linked to award expiration schedules.

Positive

• Director increased direct ownership by 25,671 shares, raising total stake to 218,784 shares.
• No shares were sold, suggesting confidence and eliminating immediate market supply.

Negative

• None.

Insights

Equity Analyst

TL;DR: Director boosted direct ownership by 25.6k shares via option exercise; no sales, modestly positive signal.

The Form 4 shows Connolly exercised awards for 25,671 AWRE shares and retained the entire allotment, lifting his direct holding to 218,784 shares. The “M” code means the shares stem from option conversion rather than open-market purchase, so cash outlay is typically minimal. However, the absence of a concurrent sale removes near-term supply and can be interpreted as insider confidence. Position size (~11.7% increase vs. pre-transaction level) is not large enough to materially alter ownership structure or signal fundamental change, but it is directionally positive. Overall impact on valuation is limited yet favorable.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41677

CytoMed THerapeutics Limited

(Translation of registrant’s name into English)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 On May 1, 2025, the Compensation Committee and the Board of Directors of CytoMed Therapeutics Limited (the “Company”) approved the issuance of ordinary shares to the following individuals as compensation for their continued service to the Company:

(i)	11,250 ordinary shares to Dr. Lucas Luk Tien Wee, Chief Clinical Officer, subject to a six-month restriction period from the date of issuance;
(ii)	25,781 ordinary shares to Ms. Goh Yvonne, Chief Financial Officer, subject to a six-month restriction period from the date of issuance;
(iii)	25,781 ordinary shares to Ms. Tan Yoong Ying, Chief Corporate Officer, subject to a six-month restriction period from the date of issuance; and
(iv)	469 ordinary shares to Dr. Yew Chak Hua, Independent Director, subject to a six-month restriction period from the date of issuance.

On July 1, 2025, the Company entered into supplemental agreements to the existing appointment agreements with each of the above individuals to formally effect the grant of the respective ordinary shares.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited.
Date: July 3, 2025	By:	/s/ Choo Chee Kong
	Name:	Choo Chee Kong
	Title:	Chairman & Director

3

FAQ

How many Aware (AWRE) shares did Director Brian D. Connolly acquire?

He acquired 25,671 common shares through an option exercise.

What was the transaction date reported in the Form 4?

The transaction took place on July 1 2025.

Did the insider sell any Aware shares in this filing?

No; the filing reports an acquisition only, with no sales disclosed.

What is Connolly’s total direct ownership after the transaction?

He now directly owns 218,784 AWRE shares.

What does transaction code “M” signify on a Form 4?

Code “M” denotes the exercise or conversion of derivative securities (e.g., stock options) into common stock.